
Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.
Castleman Disease with Corey Casper, MD
Corey Casper, MD, provides information on the diagnosis and treatment of patients with Castleman Disease (CD).
